GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
动量输入(同类管理人):
持有人广度 +12.5% ·
股份流向 -10.9% ·
净新建仓位 +11.1%
· 公式
持有人分散化:持有人数增多,合计持仓比例缩小。
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q4 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.42K | $7.92M | n/a | −1 |
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | n/a |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | n/a | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | n/a | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | n/a |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | n/a | 24.13M | $697.01M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 5.45M | -7.2% | $166.47M | 0.1% | ▼ Trim | 3 | SEC ↗ ×4 |
| 2 | Wellington Management ✦ | 4.85M | -52.1% | $148.18M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 3 | State Street Global Advisors ✦ (被动) | 2.85M | n/a | $87.04M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 2.82M | 0.0% | $86.27M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 1.89M | +38.5% | $57.76M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 1.48M | +348.5% | $45.27M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | ARK Investment Management ✦ | 1.44M | -4.8% | $43.99M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 8 | Millennium Management ✦ | 1.23M | +87.6% | $37.48M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Norges Bank ✦ (被动) | 1.19M | +1.1% | $36.44M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 873.08K | 新增 | $26.67M | 0.1% | New | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 503.10K | +14.8% | $15.37M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 279.80K | +392.6% | $8.55M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 96.40K | -88.6% | $2.95M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 45.70K | +267.5% | $1.40M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 15 | PRIMECAP Management ✦ | 43.69K | -34.0% | $1.33M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Marshall Wace ✦ | 32.09K | 新增 | $980,197 | 0.0% | New | 1 | SEC ↗ |
| 17 | Bridgewater Associates ✦ | 12.54K | -30.9% | $383,219 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 7.82K | -48.5% | $238,932 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| Point72 Asset Management | $26.67M | 0.1% |
| Marshall Wace | $980,197 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 481 持有人, 137.05M 股份, $11.53B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Director · 116 股 · $19,242
Director · 69 股 · $11,032
Director · 1.10K 股 · $192,432
Director · 826 股 · $144,550
Director · 3.30K 股 · $578,888
Director · 1.30K 股 · $229,236
Director · 971 股 · $172,330
Director · 116 股 · $20,300
Officer · 7.74K 股 · $1.38M
Officer · 4.00K 股 · $632,193
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论